Few diagnoses carry as much weight in veterinary medicine as hemangiosarcoma. It strikes fast, hides well, and often reveals itself in the most heartbreaking way, through sudden collapse, pale gums, and an emergency rush to the veterinary hospital. If your dog has been diagnosed, or if you are a dog owner simply wanting to be informed, this guide is for you.

Hemangiosarcoma (HSA) is a malignant cancer arising from the cells that line blood vessels; called vascular endothelial cells. Because blood vessels run throughout the entire body, this cancer can technically develop anywhere. In practice, however, it most commonly targets the spleen, the heart, and the liver. It is one of the most aggressive cancers known in veterinary medicine, with a well-earned reputation for rapid spread and late-stage detection.

Understanding this disease, its signs, its course, and the choices it demands, can make all the difference for affected families and their beloved companions.

What Is Hemangiosarcoma?

Hemangiosarcoma is a cancer of the vascular endothelium, meaning the cells that form the inner lining of blood vessels. These cells, in their malignant form, create abnormal, blood-filled spaces that are prone to rupture. When they do, the result can be sudden and catastrophic internal bleeding.

Unlike many cancers that grow slowly and predictably, HSA is notorious for its stealth. Tumors — especially those on the spleen — can grow silently for months, causing no obvious symptoms until they rupture. In many cases, an owner brings what appeared to be a perfectly healthy dog to the vet, only to receive devastating news.

Important: Because blood vessels are everywhere in the body, HSA can arise in virtually any tissue though the spleen, heart, and liver are by far the most common sites.

Who Gets Hemangiosarcoma? Breeds and Risk Factors

HSA is primarily a disease of middle-aged to older dogs, typically presenting between the ages of 8 and 13 years. However, certain breeds face dramatically elevated risk, pointing toward a strong genetic component.

High-Risk Breeds

• German Shepherd Dog — the most heavily affected breed
• Golden Retriever — exceptionally high lifetime risk
• Labrador Retriever
• Boxer
• Doberman Pinscher
• Skye Terrier
• Portuguese Water Dog

Golden Retrievers deserve special mention. Studies suggest that approximately 1 in 5 Golden Retrievers will develop some form of cancer during their lifetime, and HSA represents a significant portion of those diagnoses. The Golden Retriever Lifetime Study, one of the largest veterinary cancer research projects ever undertaken, has been investigating these patterns to better understand and eventually prevent the disease.

While breed is the single largest risk factor, male dogs may be slightly more predisposed than females, and spayed/neutered dogs have shown some increased risk in certain studies — though the data on this remains mixed.

Preventive Tip: Any large or senior dog, especially from a high-risk breed, warrants regular screening ultrasounds as part of preventive wellness care.

Types and Locations: Not All HSA Is the Same

Veterinary oncologists classify hemangiosarcoma into three primary forms based on where it originates. This distinction matters enormously for prognosis and treatment options.

---

Type Location Relative Frequency Prognosis

---

Visceral — Splenic Spleen ~50% of cases Guarded to poor

Visceral — Cardiac Right ~25% of cases Poor atrium/heart

Visceral — Hepatic Liver Often Poor secondary/metastatic

Dermal (Cutaneous) Skin surface Less common Favorable with surgery

Hypodermal/Subcutaneous Under the skin Less common Intermediate

Splenic HSA

The spleen is the most common primary site for hemangiosarcoma. Splenic HSA tumors can grow to remarkable size before causing symptoms, often discovered only when they rupture and cause hemoabdomen — a life-threatening accumulation of blood in the abdominal cavity. This event presents as sudden collapse, profound weakness, and pale or white gums, and constitutes a true veterinary emergency.

An important and somewhat hopeful nuance: not all large splenic masses are hemangiosarcoma. Approximately one-third of large splenic masses in dogs are benign conditions such as nodular hyperplasia or splenic hematoma. This is why histopathology, microscopic examination of removed tissue,  is essential for a definitive diagnosis.

Cardiac HSA

Hemangiosarcoma of the heart most commonly arises from the right atrium. As the tumor grows, it often causes pericardial effusion, fluid accumulating around the heart, which compresses the heart and impairs its ability to pump blood. This condition, called cardiac tamponade, can cause rapid deterioration and death if not addressed.

Dogs with cardiac HSA often show exercise intolerance, episodes of fainting (syncope), weakness, and labored breathing. The condition is especially insidious because these symptoms can mimic many other cardiac diseases.

Dermal and Subcutaneous HSA

Cutaneous (skin surface) HSA presents as pigmented nodules, often appearing red, purple, or black, on or just under the skin.

This form carries a substantially better prognosis than visceral disease and may be curable with surgery alone in some cases, particularly when the lesion is small and confined. 

Sun exposure on lightly pigmented, sparsely haired skin (such as the ventral abdomen) has been identified as a potential contributing factor in dermal HSA.

Recognizing the Signs: What to Watch For

The clinical presentation of HSA varies considerably depending on the tumor's location and whether it has ruptured. Many dogs show no obvious signs until a crisis occurs.

Signs of Splenic or Abdominal HSA

• Sudden collapse or extreme weakness
• Pale, white, or grayish gums
• Rapid, shallow breathing
• Distended or painful abdomen
• Episodes of weakness that seem to improve on their own — a hallmark of slow, self-sealing bleeds
• Progressive lethargy and exercise intolerance over weeks to months
• Decreased appetite and unexplained weight loss

Signs of Cardiac HSA

• Exercise intolerance or sudden reluctance to exercise
• Fainting or collapsing spells
• Muffled heart sounds
• Distended jugular veins
• Fluid accumulation in the abdomen (ascites)
• Rapid or irregular heartbeat

Signs of Cutaneous HSA

• Visible skin nodule, often dark red, purple, or black
• Ulceration or spontaneous bleeding from a skin mass
• Rapid growth of a previously stable skin lesion

Warning Sign: The "good day, bad day" pattern, where a dog seems ill, then recovers without treatment,  is a classic and underrecognized warning sign. This often reflects small bleeds that temporarily clot, followed by rebleeding. It should always prompt immediate veterinary evaluation.

Diagnosis: How Hemangiosarcoma Is Identified

Diagnosing HSA requires a combination of laboratory work, imaging, and ultimately tissue analysis. No single test is sufficient on its own.

Laboratory Testing

A complete blood count (CBC) in dogs with HSA frequently reveals anemia --- sometimes severe — along with thrombocytopenia (low platelet count) and the presence of schistocytes (fragmented red blood cells), which result from red cells being mechanically damaged as they pass through abnormal tumor vasculature. Liver enzyme elevations are common when hepatic involvement is present. Coagulopathies are also frequently observed.

Imaging

Abdominal ultrasound is a cornerstone of HSA diagnosis, allowing visualization of splenic or hepatic masses, assessment of lymph nodes, and detection of free abdominal fluid. Echocardiography (cardiac ultrasound) is essential when cardiac involvement is suspected. Thoracic radiographs are used to screen for pulmonary metastasis. CT scanning is increasingly utilized for comprehensive staging prior to surgery.

Cytology and Histopathology

Fine needle aspirate cytology of splenic masses is generally unreliable for diagnosing HSA, the cellular yield is often poor and interpretation is difficult. Definitive diagnosis requires histopathology: microscopic examination of surgically removed tissue by a veterinary pathologist. This is typically obtained at the time of splenectomy.

Staging

---

Stage Description Implications

---

Stage I Tumor confined to primary Best surgical candidate site; no rupture

Stage II Ruptured tumor, regional lymph Surgical + chemotherapy node involvement, or cardiac standard involvement

Stage III Distant metastasis present Palliative focus; guarded prognosis

It is critical to understand that the majority of dogs with visceral HSA --- even those staged as Stage I based on imaging — already harbor microscopic metastatic disease at the time of diagnosis. This biological reality underlies the uniformly guarded prognosis associated with this disease.

Treatment Options

Treatment for hemangiosarcoma involves difficult decisions that balance potential benefit with quality of life, financial considerations, and individual dog factors. There is no cure for most forms of this disease, but meaningful extensions of good-quality time are achievable.

Surgery

Splenectomy — surgical removal of the spleen — is the primary treatment for splenic HSA and serves both therapeutic and diagnostic purposes. It removes the primary bleeding source, provides tissue for definitive diagnosis, and may extend survival. Without surgery, median survival following splenic HSA diagnosis is measured in days to weeks. With surgery alone (no chemotherapy), median survival is approximately 1 to 2 months.

For cardiac HSA, complete surgical resection is rarely achievable. Pericardectomy (removal of the pericardial sac) provides palliative relief from cardiac tamponade and may extend comfort. For cutaneous HSA, wide surgical excision with clean margins is the treatment of choice and may be curative.

Chemotherapy

Adjuvant chemotherapy following surgery is the current standard of care for visceral HSA. Doxorubicin-based protocols are most commonly employed, either as a single agent or in combination (VAC protocol: Vincristine, Doxorubicin, and Cyclophosphamide). With surgery plus chemotherapy, median survival for splenic HSA extends to approximately 4 to 6 months. Approximately 10% of treated dogs survive to 12 months.

While these survival times may appear modest, it is important to recognize that many dogs maintain excellent quality of life during this period. The goal of treatment is not simply to extend life, but to preserve meaningful, comfortable time.

Emerging and Investigational Therapies

Research into HSA treatment is active, and several promising avenues are under investigation:

• Etoposide-based metronomic protocols — low-dose continuous oral chemotherapy showing early promise
• Toceranib phosphate (Palladia) — a tyrosine kinase inhibitor with limited but emerging evidence for HSA
• Immunotherapy and cancer vaccines — under active investigation in veterinary oncology research programs
• Liposomal doxorubicin formulations — improved drug delivery to tumor sites

Prognosis: What to Realistically Expect

---

Scenario Median Survival

---

Splenic HSA, surgery alone 1--2 months

Splenic HSA, surgery + chemotherapy 4--6 months

Cardiac HSA (any treatment) 1--4 months

Dermal HSA, surgery alone 12--20 months

Subcutaneous HSA, surgery + chemotherapy ~6 months

These statistics represent population medians — meaning half of all dogs do better, and half do worse. Some dogs with splenic HSA treated aggressively live well beyond a year. The prognosis is genuinely unpredictable at the individual level, which is both discouraging and, at times, a source of hope.

Perspective: Quality of life is the paramount consideration. A dog that is comfortable, engaged, and enjoying daily pleasures while living 4 months on treatment is not a treatment failure — this is a meaningful success.

Integrative and Supportive Care

Many veterinary oncologists and holistic practitioners incorporate supportive therapies alongside conventional treatment. While these approaches should never replace evidence-based medicine, several have demonstrated enough promise to merit discussion.

Nutrition

Cancer metabolism research supports a diet that is high in quality protein and fat while limiting simple carbohydrates — a principle sometimes called metabolic cancer nutrition. Omega-3 fatty acids (EPA and DHA from fish oil) have demonstrated anti-inflammatory and potentially anti-tumor effects in veterinary and human oncology research. A diet free from artificial preservatives, dyes, and by-products is generally recommended.

Nutraceuticals and Herbal Support

• Yunnan Baiyao:  A traditional Chinese herbal formulation widely used in veterinary oncology for its hemostatic (bleeding control) properties. Many oncologists incorporate it into care for bleeding tumors, though robust clinical trial data remains limited.
• Turkey Tail Mushroom (PSK/PSP from Coriolus versicolor): A 2012 study by Dr. Dorothy Cimino Brown at the University of Pennsylvania found that dogs with splenic HSA receiving I'm-Yunity (a standardized PSK product) had a median survival comparable to or exceeding surgery-plus-chemotherapy. The findings are preliminary but intriguing.
• Reishi mushroom (Ganoderma lucidum): Immunomodulatory properties with emerging evidence in oncology contexts
• Astragalus: Traditional adaptogenic herb with immune-supporting properties

Other Supportive Modalities

• Veterinary acupuncture: Palliative pain management and quality-of-life support
• Photobiomodulation (laser therapy): Emerging supportive care for pain and healing
• CBD/hemp-derived cannabinoids: Anecdotal reports of comfort improvement; under active research

Always consult your veterinary oncologist before introducing supplements, as some may interact with chemotherapy agents or have contraindications in individual patients.

The Emergency Situation: Hemoabdomen

When a splenic or hepatic HSA tumor ruptures, the result is hemoabdomen --- potentially life-threatening internal hemorrhage. This constitutes a true veterinary emergency. Recognizing the signs and acting immediately can make the difference between life and death.

Emergency Signs

• Sudden collapse or inability to rise
• Pale, white, grayish, or yellowish gums
• Rapid, shallow, or labored breathing
• Distended, tense, or painful abdomen
• Rapid heart rate with weak pulse
• Profound weakness with disorientation

Emergency Action: Do not wait to see if your dog improves on their own. If you observe these signs, go to an emergency veterinary facility immediately. Time is critical in hemoabdomen.

At the hospital, stabilization will include IV fluid therapy, oxygen support, and potentially blood transfusion. The decision to proceed to emergency surgery will depend on the dog's cardiovascular stability and the owner's wishes regarding treatment intent.

Making Treatment Decisions: A Framework for Families

Few medical situations are more emotionally demanding than a hemangiosarcoma diagnosis. The disease is aggressive, the prognosis is guarded, and the decisions are deeply personal. There is no universally right answer — only the answer that is right for your dog, your family, and your values.

Questions to Discuss With Your Veterinary Team

• What stage is the disease, and what does that mean for expected outcomes?
• What is the goal of treatment — extending life, preserving quality of life, or both?
• What are the expected side effects of each treatment option?
• What does palliative or hospice care look like for this condition?
• How will we recognize when quality of life is declining, and what does that process look like?
• What complementary therapies might be appropriate alongside conventional treatment?

Both aggressive treatment and compassionate hospice care are legitimate, loving choices. A dog who receives palliative care — focused entirely on comfort, joy, and dignity — is being given an extraordinary gift. So is a dog whose family chooses to pursue every available treatment option.

Early Detection: Can We Do Better?

The greatest limitation in HSA management is its late-stage presentation. By the time most dogs show symptoms, the disease has already spread microscopically. This has driven growing interest in early detection strategies.

Annual Screening Ultrasound

For high-risk breeds — particularly Golden Retrievers, German Shepherds, and Labrador Retrievers — annual or biannual abdominal ultrasounds beginning around age 6 to 7 are increasingly recommended by veterinary internists and oncologists. While not guaranteed to catch all tumors before rupture, this screening approach has identified early-stage lesions that allowed for planned, elective surgery with improved outcomes.

Liquid Biopsy Research

Exciting research is underway exploring blood-based cancer detection, sometimes called "liquid biopsy," that could identify cancer-associated DNA fragments or other biomarkers in the bloodstream before tumors cause symptoms. Several companies and academic institutions are actively developing and validating these tests for dogs, and they represent perhaps the most promising avenue for improving outcomes in this disease.

Emerging Technology: The Nu.Q Canine Cancer Screen and similar tests are emerging tools for early cancer detection in dogs. Ask your veterinarian about whether screening options are appropriate for your dog.

Research and Hope

Hemangiosarcoma research in dogs is not only important for veterinary medicine — it also has significant implications for human angiosarcoma, a rare and similarly aggressive vascular cancer affecting people. The shared biology between canine and human vascular cancers has made dogs valuable natural models for cancer research, and several collaborative studies between veterinary and human oncology researchers are underway.

Organizations such as the Canine Health Foundation, Morris Animal Foundation, AKC Canine Health Foundation, and numerous veterinary school research programs are actively funding HSA research. Clinical trials for novel treatments are available at many academic veterinary centers and represent meaningful options for some patients.

The pace of progress in veterinary oncology is accelerating. Immunotherapy, targeted molecular therapies, and early detection technologies that seemed distant just a decade ago are now entering clinical practice. While hemangiosarcoma remains a formidable adversary, the outlook for future generations of dogs is meaningfully brighter than it was even five years ago.

Key Takeaways for Dog Owners

• Hemangiosarcoma is one of the most common and aggressive cancers in dogs, particularly affecting large breeds and seniors.
• It often presents as a sudden emergency — sudden collapse with pale gums is a classic first presentation.
• The "good days and bad days" pattern of intermittent weakness can signal slow internal bleeding and should never be dismissed.
• Treatment buys meaningful time — months of good quality life --- though cure is rare for visceral forms.
• Both aggressive treatment and palliative care are valid, loving choices depending on individual circumstances.
• Regular screening ultrasounds in high-risk breeds may enable earlier detection and better outcomes.
• Integrative therapies — nutrition, Yunnan Baiyao, mushroom extracts — can complement conventional care.
• Research is advancing rapidly, and clinical trial participation may offer additional options.

Frequently Asked Questions

Is hemangiosarcoma painful for dogs?

Hemangiosarcoma itself may not cause obvious pain in the early stages, which is part of why it goes undetected for so long. However, internal bleeding, tumor growth, and the effects of pericardial effusion can cause significant discomfort. Dogs are stoic animals and often mask pain well. If you notice changes in posture, reluctance to move, labored breathing, or unusual restlessness, these may indicate discomfort that warrants prompt veterinary assessment.

Can hemangiosarcoma be cured?

For visceral (internal organ) hemangiosarcoma, cure is rare. The disease almost universally has micrometastatic spread at the time of diagnosis, meaning microscopic cancer cells have already traveled to other sites. Treatment is aimed at extending good-quality life rather than achieving cure. Dermal (skin surface) HSA is a notable exception — when caught early and surgically removed with clean margins, cure is possible in a meaningful percentage of cases.

How quickly does hemangiosarcoma progress?

HSA is one of the fastest-progressing cancers in veterinary medicine. Visceral tumors can grow substantially within weeks. Without intervention, median survival following diagnosis of splenic or cardiac HSA is days to weeks. Even with aggressive treatment, the disease typically progresses within months. This rapid trajectory is one reason emergency presentations are so common — dogs can appear healthy until a tumor suddenly ruptures.

Should I pursue surgery if my dog is diagnosed with splenic HSA?

This is a deeply personal decision that depends on your dog's overall health, age, and your goals for their care. Surgery (splenectomy) does two important things: it removes the immediate bleeding risk and it provides the tissue needed for a definitive diagnosis. Without surgery, it is not possible to confirm whether a splenic mass is malignant or benign. Many families pursue surgery to both stabilize their dog and gain accurate diagnostic information, then decide about further treatment based on what the pathology reveals. A board-certified veterinary oncologist can help you weigh the options for your individual dog.

What is Yunnan Baiyao and should my dog take it?

Yunnan Baiyao is a traditional Chinese herbal blend that has been used for centuries for its hemostatic (blood-stopping) properties. In veterinary oncology, it is widely used in dogs with bleeding tumors --- particularly splenic HSA — to help slow hemorrhage and potentially extend the time before a catastrophic bleed. Many veterinary oncologists incorporate it into their management protocols. The evidence base is largely anecdotal and limited clinical trial data exists, but its safety profile is generally considered favorable at typical doses. Always discuss with your veterinarian before starting any supplement.

Is hemangiosarcoma hereditary? Can I screen for it?

There is a clear genetic predisposition in certain breeds, particularly Golden Retrievers, German Shepherds, and Labrador Retrievers. However, the specific genes responsible have not yet been fully identified, and there is no commercially available hereditary screening test that can predict whether an individual dog will develop HSA. Ongoing research --- including the Golden Retriever Lifetime Study — is actively working to identify genetic markers that may one day enable targeted screening. For now, breed awareness and regular veterinary monitoring remain the primary preventive strategies.

My dog collapsed suddenly — could it be hemangiosarcoma?

Sudden collapse in a middle-aged or older large-breed dog is a medical emergency that should be treated as such immediately, regardless of cause. Splenic HSA rupture is one of the most common causes of acute collapse with internal hemorrhage in dogs, but there are other serious conditions that can present similarly, including immune-mediated hemolytic anemia, other abdominal masses, and cardiac arrhythmias. Do not wait to see if your dog recovers. Go to an emergency veterinary facility right away. Time is critical.

How do I know when it is time to say goodbye?

This is the most heartbreaking question any pet owner faces, and there is no universal answer. Veterinary hospice specialists often use quality-of-life scales — such as the HHHHHMM Scale developed by Dr. Alice Villalobos — to help families assess pain, appetite, hygiene, happiness, mobility, and more. In general, when a dog is experiencing more bad days than good, when they have lost interest in things they once enjoyed, or when they are in unmanageable pain or distress, it may be time to have an honest conversation with your veterinarian about humane euthanasia. Choosing a peaceful death at the right moment is one of the most loving gifts we can give our animal companions.

Are there clinical trials available for hemangiosarcoma?

Yes. Veterinary teaching hospitals and research institutions regularly conduct clinical trials for HSA. Trials may involve novel chemotherapy agents, immunotherapy, vaccine therapies, or other investigational approaches. Participation in a clinical trial may provide access to cutting-edge treatments at reduced or no cost, while also contributing to the scientific knowledge that may help future patients. Ask your veterinarian for a referral to a board-certified veterinary oncologist, or search the Veterinary Cancer Society's clinical trial database for trials currently enrolling patients.

This article is intended for educational purposes only and does not constitute veterinary medical advice. Always consult a licensed veterinarian or board-certified veterinary oncologist for guidance specific to your dog's health needs.